Pharma's middlemen see shares suffer as challenges grow

Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.